This company has been acquired
Marrone Bio Innovations Management
Management criteria checks 4/4
Key information
Kevin Helash
Chief executive officer
US$416.6k
Total compensation
| CEO salary percentage | 97.0% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.05% |
| Management average tenure | 4.5yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21
Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$21m |
| Dec 31 2021 | US$417k | US$404k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$1m | US$155k | -US$20m |
Compensation vs Market: Kevin's total compensation ($USD416.64K) is below average for companies of similar size in the US market ($USD787.45K).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin Helash (57 yo)
1.9yrs
Tenure
US$416,642
Compensation
Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$416.64k | 0.045% $ 65.9k | |
| Founder | 16.5yrs | US$254.58k | 1.21% $ 1.8m | |
| Chief Compliance Officer | 8.3yrs | US$316.74k | 0.013% $ 18.9k | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Senior VP of Research Development & Chief Technical Officer | 5.3yrs | no data | 0.022% $ 31.4k | |
| Director of Marketing | no data | no data | no data | |
| Director of National Sales & Account Management | 3.8yrs | no data | no data | |
| Senior Vice President of International Sales | 1.4yrs | no data | 0.0026% $ 3.7k | |
| Senior VP of Regulatory & Government Affairs and Chief Sustainability Officer | 5.9yrs | no data | 0.0026% $ 3.8k |
4.5yrs
Average Tenure
61.5yo
Average Age
Experienced Management: MBII's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$416.64k | 0.045% $ 65.9k | |
| Founder | 16.5yrs | US$254.58k | 1.21% $ 1.8m | |
| Independent Director | 3.9yrs | US$83.83k | 0% $ 0 | |
| Independent Chairman | 4.4yrs | US$112.02k | 0.0074% $ 10.8k | |
| International Science Advisory Panel Member | no data | no data | no data | |
| Independent Director | 6.2yrs | US$93.23k | 0.0032% $ 4.6k | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| Independent Director | 3.9yrs | US$81.82k | 0% $ 0 |
4.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: MBII's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/13 11:37 |
| End of Day Share Price | 2022/07/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marrone Bio Innovations, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Benjamin Kallo | Baird |
| Benjamin Klieve | B. Riley Wealth |